Datapoint: BCBS Vermont Sues Teva Over Copaxone Prices
Blue Cross and Blue Shield of Vermont has filed a lawsuit against Teva Pharmaceuticals, alleging the drugmaker uses unethical marketing tactics and anticompetitive practices to keep prices for its multiple sclerosis drug, Copaxone, “excessively” high and block any generic competition. The suit highlights Copaxone’s 1997 price of $769, compared to more than $5,800 by 2017. About 80% of all insured lives in the U.S. have covered or better access to Copaxone under the pharmacy benefit. Among BCBS Vermont’s formularies, 91% of members have preferred access to Copaxone with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 8/24/22